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Abstract
A native-like smooth muscle filamentous myosin system was characterized from an enzyme kinetic point of view. The
system contains endogenous myosin light chain kinase (MLCKase) and calmodulin (CM) (A. Sobieszek, J. Muscle Res. Cell
Motil. 11 (1990) 114^124) and is, therefore, well suited for testing the action of CM-antagonists or other inhibitory
compounds. However, this has not been done due to its complexity. The characterization of the system includes: (1)
derivation of a relationship for rate of myosin phosphorylation in terms of total CM, free Ca2 and total MLCKase
concentrations, which includes only three binding constants; and (2) derivation of relationships between fractional inhibition
rate (vi/vo) and total inhibitor concentration (It) which cover most of the inhibitory mechanisms applicable to the myosin
system or to other CM-dependent enzymes. The three binding constants were subsequently evaluated from experimental data
for filamentous myosin and for its isolated regulatory light chain (ReLC) using a non-linear regression software. They
indicated differences in the interaction of myosin filament with the active CM^MLCKase complex in comparison to that of
the isolated ReLC. The derived vi/vo versus It relationships, together with the software, make it possible to evaluate the
inhibition constants and binding stoichiometries of CM-antagonists and other compounds inhibiting myosin phosphoryla-
tion. This approach was successfully applied to experimental data on inhibition of MLCKase by amiloride, cadmium, or
CM-binding peptide (M-12) for simple mechanisms. For more complex mechanisms, inhibition by calmidozolium,
trifluoperazine or melittin, the analysis showed that only calmidozolium acted specifically at the CM level in a multiple-site
activator-depletion mechanism. Melittin and trifluoperazine inhibited the phosphorylation rate by a novel substrate-and-
activator depletion mechanism, in which additional inhibition of the substrate resulted in the removal of the inhibition at
lower range of the antagonists’ concentration. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Myosin light chain kinase (MLCKase) is the key
regulatory enzyme of smooth muscle which activates
myosin by phosphorylation of the myosin 20-kDa
regulatory light chain (ReLC) and initiates contrac-
tion (for reviews see [1^5]). Activity of the MLCKase
fully depends on the presence of calmodulin (CM)
and Ca2. This contrasts with most of the other
CM-dependent enzymes which possess high and var-
iable levels of CM-independent activity and, depend-
ing on conditions, CM modi¢es this level to a di¡er-
ent degree (see review by [6]). This absolute CM-
dependence makes MLCKase a very suitable enzyme
for studying the action of various drugs and CM-
antagonists. Another advantage of the MLCKase
phosphorylation system is the availability of at least
three substrates that include intact myosin, its iso-
lated regulatory light chain (ReLC) and a commer-
cially available very small synthetic peptide (Kemp-
tide) of the sequence corresponding to that of the
ReLC phosphorylation site (see [7]). Of these, the
intact myosin is particularly convenient because it
is normally puri¢ed with stoichiometric amounts of
endogenous MLCKase and CM [8]. The other two
substrates require addition of puri¢ed MLCKase and
CM, but are also convenient as substrates alone be-
cause of their resistance to denaturation.
Despite these advantages, the MLCKase phos-
phorylation system has not widely been used as a
CM-testing system. The main reason is the complex-
ity of the interaction between MLCKase and CM
during active complex formation due to the presence
of four Ca2 binding sites on CM. Thus, the system
is, in principle, characterized by nine binding con-
stants [9]. In the present report, I have characterized
the system from an enzyme kinetic point of view. At
the same time, I have derived some fractional inhi-
bition rate relationships which should make the sys-
tem more attractive for computer assisted analysis of
the action of CM-inhibitors.
2. Materials and methods
2.1. Protein preparations
Turkey gizzard myosin, MLCKase and CM were
used throughout. The myosin was puri¢ed from
freshly extracted actomyosin as described previously
[10]. A myo¢bril-like preparation [11] pre-extracted
for MLCKase was used as a as starting material (see
[12]). This native-like ¢lamentous myosin contained
relatively high and approximately equimolar
amounts of endogenous MLCKase and CM [8];
therefore, it was used without addition of puri¢ed
MLCKase and CM. The established molar ratio of
MLCKase to myosin was about 1:150. The myosin
also contained low levels of an endogenous myosin
light chain phosphatase. Its presence was only ap-
parent after 5^15 min incubation when ATP became
depleted by myosin ATPase. As result of its very
low content, this phosphatase did not e¡ect our ini-
tial rate measurements. This was con¢rmed by con-
trol experiments carried out in the presence and ab-
sence of 100 nM of Microcystin L-R. In addition, its
substrate (phosphorylated myosin) was absent at the
o¡set of the measurements and the assay time was
relatively short (see below).
For the rate measurements with ReLC, or with
CM- and MLCKase-free myosin puri¢ed MLCKase
and CM were added to these substrates. The kinase
was initially extracted from the same myo¢brils (see
above) and was puri¢ed by the method of Sobieszek
and Barylko [13] as modi¢ed by Sobieszek [14]. The
myosin was freed of the endogenous CM and
MLCKase by a passage through a CM-a⁄nity and
phenyl Sepharose 6B-CL columns connected in tan-
dem [15]. The ReLC was isolated from myosin by the
method described by Perrie and Perry [16] and puri-
¢ed on DEAE Sepharose 6B-CL to remove the en-
dogenous CM and separate it from the essential light
chain [17]. Crude CM was obtained as a by-product
of MLCKase puri¢cation and was puri¢ed as de-
scribed in [18]. Commercially synthesized CM bind-
ing peptide was generously provided by Dr. A.R.
Means of Duke University, Durham, NC, USA.
2.2. Phosphorylation assays
The experimental details for the measurements of
initial phosphorylation rates and composition of the
bu¡er media used were described previously [14,15].
In short, the assay bu¡er contained (in mM): KCl,
60; MgCl2, 2; DTE, 1; CaCl2, 0.1; imidazole, 10;
with pH adjusted to 7.0 at 25‡C. The substrate^CM^
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MLCKase mixes, were added to increasing amounts
of CM and small volumes of Ca/EGTA bu¡ers con-
taining increasing concentrations of EGTA/CaCl2
and decreasing concentrations of EGTA. The free
Ca2 was calculated by using an apparent binding
constant (Kapp) of EGTA for Ca2 of Kapp =
1.47W1037. The 125 Wl assays were initiated by the
addition of Q-32PWATP to a ¢nal concentration of
0.6 and 0.3 mM, respectively, for the myosin and
the ReLC. They were terminated by addition of 50
Wl of a saturated guanidine hydrochloride solution
with an incubation time of 40^60 s for myosin and
of 1^2 min for the ReLC. After spotting 170 Wl on
2U4 cm Wathman (Maidstone, UK) 3MM chroma-
tographic paper, the paper pieces were washed exten-
sively in TCA and ethanol and counted, in water, in
a scintillation counter.
The e¡ects of CM-antagonists or other inhibitors
were measured in a similar way using either the na-
tive-like myosin or the systems reconstituted from
MLCKase-, and CM-free substrates (myosin or its
isolated ReLC) with added CM and MLCKase. In
all cases, increasing amounts of an antagonist, or an
inhibitor, were added to these substrate^CM^
MLCKase mixes and the rates were measured during
20 or 30 s incubation. The concentrations of myosin
and ReLC were 30^50 and 150^250 WM, respectively.
2.3. Computer analysis
Experimental data on the inhibition of the phos-
phorylation rate were analyzed by non-linear regres-
sion computer software developed for the present
studies in the early 80 s. There are now more con-
venient commercially available software packages of
this type e.g. ‘Scientist’ from MicroMath, Salt Lake
City, UT. Our software consisted of a program for
the ‘minimalization’ of a function with up to 20 pa-
rameters (independent variables), a function-plotting
capacity, and a data manipulation block. The David-
son^Fletcher^Powell algorithm (see [19]) was used in
the minimalization program of the M2-function be-
tween experimental and theoretical values of a mod-
el. The minimalization permitted the use of approx-
imate starting values of the parameters, but the
maximum number of parameters should be no great-
er than the degrees of freedom in a given mathemat-
ical model.
3. Results
3.1. Kinetic considerations
The reaction catalyzed by MLCKase involves two
substrates (ATP and myosin) and two products
(phosphorylated myosin and ADP) but at relatively
high concentration of one of the substrates (usually
ATP) it can be considered as a single substrate reac-
tion. The activity of the kinase fully depends on the
presence of calmodulin (CM); therefore, under
steady-state conditions, the reaction can be charac-
terized as follows:
E  AIKa EA  SIKs EASÿ!
kp
P EA; 1
where E and A represent, respectively, concen-
trations of the kinase and its activator (CM) while
S and P correspond to concentrations of unphos-
phorylated and phosphorylated myosin. EA is the
concentration of the active CM^MLCKase complex
while EAS is the concentration of the ternary com-
plex.
Formation of the active CM^MLCKase complex
depends on the presence of Ca2 which is bound by
CM and increases the a⁄nity of CM for MLCKase
some 106-fold. There are four Ca2-binding site on
CM giving rise to ¢ve possible CM^kinase com-
plexes. From the already published data, it appears
that only the one with four sites occupied is active
(Ca24 WCMWMLCKase). This makes it possible to
characterize the kinase^CM interaction by three
binding constants: the ¢rst representing the average
a⁄nity of Ca2 for CM (KCa); the second corre-
sponding to the a⁄nity of Ca24 WCM for MLCKase
(Ka) ; and the third re£ecting this a⁄nity after for-
mation of the ternary substrate^enzyme complex
(KCM). With this approximation and consistent
with classical enzyme kinetics [20], the concentration
of the Ca24 WCM complex is equal to:
Ca24 WCM 
Ca2
KCa
 
4
1 Ca
2
KCa
 
4
WCM  CM 
1 KCaCa2
 
4
:
2
Assuming that the fractional activity (v/Vm) is equal
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to the concentrations’ ratio of the active CM^
MLCKase complex to that of the total kinase, the
overall rate equation describing the fractional en-
zyme activity in terms of free Ca2 and free CM
concentrations is obtained by substituting Eq. 2 in
Michaelis^Menten equation:
v
Vm
 Ca
2
4 WCM
 
KCM  Ca24 WCM
 ;
and v  VmW CM f
KCM W 1 KCMCa2
 
4  CMf
3
This relatively simple formula has one disadvant-
age because it requires knowledge of the free CM
concentration which is very di⁄cult to measure ex-
perimentally. The free Ca2 concentration is usually
known when Ca/EGTA bu¡er system is used. The
problem was resolved by introducing the Ka dissoci-
ation constant together with CM mass balance (see
[18]). After resolving the corresponding square root
equation
CMf  CMt3EA; 4
where
EA  1=2WEt  CMt  Ka
3

Et  CMt  Ka234WEtWCMt
q
:
The Ka dissociation constant is equal to the KCM
constant if there is no cooperativity in activation of
the MLCKase. In the case of positive cooperativity,
KasKCM ; if Ka6KCM, a negative cooperativity in
activation of the kinase by the Ca2/CM complex is
indicated.
3.2. Characterization of the myosin phosphorylating
system
The mathematical model derived above was ap-
Fig. 1. Evaluation of kinetic parameters that characterize MLCKase activation by Ca2 and CM for the two substrate systems used:
isolated ReLC (A); and the kinase- and CM-free ¢lamentous myosin (B). The phosphorylation rates of MLCKase (50 nM) were
measured at di¡erent CM (total) and Ca2 (free) concentrations. The optimal kinetic constants obtained from several experiments of
this type are given in Table 1. The concentrations of myosin and ReLC were 30 and 500 WM, respectively. The solid curves in this
and the following ¢gures correspond to the best ¢t obtained after application of the non-linear regression analysis together with a
mathematical model in this ¢gure Eq. 3 together with Eq. 4.
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plied to experimental data using a non-linear regres-
sion approach. The model includes two independent
variables, namely total CM and free Ca2 concentra-
tions. The experimental data involved, therefore,
measurements of the activity (i.e. initial phosphoryl-
ation rates) as a function of total CM and free Ca2
concentrations. The model imposes no restriction on
the enzyme concentration, but the substrates, in our
case CM-, and MLCKase-free ¢lamentous myosin or
the isolated ReLC, were at saturating levels. After
optimalization of a family of the CM-activation
curves, evaluation of not only the Ka and KCM con-
stants, but also the KCa binding constants as well as
the maximal speci¢c activity (Vm) was possible. It is
apparent from Fig. 1 that the model approximated
the data for both the substrates rather well and pro-
vided accurate values of the constants. The average
values obtained from several such families of curves
with corresponding standard deviations are given in
Table 1. Signi¢cantly, the values indicate that activa-
tion of MLCKase by CM was positively cooperative
when ¢lamentous myosin was used as the substrate
(i.e. Ka6KCM), but with isolated ReLC, we observed
increase in value of the dissociation constant (i.e.
KasKCM). Thus, CM-activation with the ReLC
was negatively cooperative exclusively at this isolated
association step. Positive cooperativity of MLCKase
activation by Ca2 was not apparent in this analysis
because the value of the KCa constant corresponds to
an arithmetical average of the four intrinsic binding
constants representing the four Ca2 binding sites of
CM. It can be readily shown that this well known
binding is always positively cooperative (for referen-
ces see [21].
More complete kinetic characterization of the
MLCKase system requires the estimation of an addi-
tional elementary kinetic constant, the Ks constant
which characterizes the binding a⁄nity of the active
CM^MLCKase complex for the substrate. The Ks
constant for the myosin ¢laments was experimentally
determined from the classical rate versus concentra-
tion relationship (Fig. 2). Values for Ks are given in
Table 1. As before, the CM-, and MLCKase-free
¢lamentous myosin used in this determination and
known catalytic amounts of puri¢ed kinase and
CM were added. In an analogous way, I obtained
the Ks constant which characterize heavy meromyo-
sin (HMM) fragment of myosin as a MLCKase sub-
strate (Table 1), but this related to the isolated ReLC
had been established previously [14].
Evaluation of the Ks constant for myosin (shown
in Fig. 2) represents another simple illustration of the
non-linear regression procedure which, in this case,
Table 1
Kinetic constants characterizing phosphorylation of a smooth
muscle myosin or its isolated regulatory light chain
Substrate Constant Value (WM)
MY Ks 7.3 þ 0.5
Ka 8.4 þ 2.0W1033
KCM 1.0 þ 0.5W1033
KCa 1.0 þ 0.5
ReLC Ks 28a
Ka 6.0 þ 2.5W1033
KCM 14.0 þ 3.0W1033
KCa 3.2 þ 2.0
HMM Ks 4.6
aTaken from [14].
Fig. 2. Determination of the Ks kinetic constants for the ¢la-
mentous myosin system. Initial phosphorylation rates of suspen-
sions of myosin ¢laments were determined in the presence of
5 nM puri¢ed MLCKase and 10 nM CM. The 7.3 WM value
obtained (Table 1) was used in the computer evaluation of the
inhibition constants (Table 3).
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Table 2
Fractional inhibition rate relationships for most of the inhibition mechanisms applicable to CM-dependent enzyme systems
Type of inhibition Formula: (vi/vo = ) Approximations
Competitive Ki W Ks  S 
KsW Ki  I   Ki WS
ItWI
Non-competitive Ki
Ki  I
ItWI
Uncompetitive Ki W Ks  S 
Ki WKs  SW Ki  I 
ItWI
Mixed type S  Ks
KsW 1 IKi
 
 SW 1 I
Kis
  ItWI
Mixed type (Et9It)
It3EtWb a2  4WaWbWEtp 3I t3EtWb a
2WEtWb
Kis = Ksi
where
a  1 Ks
S
; b  1
Ksi
 Ks
SWKi
Multiple site Ki 0
Ki 0  In
See [20]
Substrate inhibition Kesi WKsi  SWKs  S
Kesi WKsi  SWKs  S  I tWS
StWS
Substrate depletion SWKs  St
StWKs  S
StWS
where
S  1=2W

I t3St  Ksi2  4Ksi WSt
q
3I t3St  Ksi
Substrate combination SWKs  StWKsi
StWKsWKsi  St3S  SWKsi
StWS+SI, ItWI+SI
where S is as above
Activator depletion see text
Activator inhibition KaWKs  AWS  KsWA
KaWKs  AWS  Ai WKeai
ItWI
and
Ai  AWItKai  A
Activator combination AWKaWKs  AtWKs  AtWSWKeai
AtWKaWKs  AtWKs  AtWSWKeai  KaWKsWAt3A
ItWI+Ai, AtWA+Ai
where
A  1=2W

I t3At  Kai234WKai WAt
q
3I t3At  Kai
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provided values of the two elementary constants (Ks
and Vm) without the need to replot the data in a
double reciprocal form.
3.3. Fractional inhibition rate relationships
Analysis of inhibition of the myosin phosphorylat-
ing system or CM-dependent enzymes can be facili-
tated by use of a non-linear regression software pro-
vided that relationships between the fractional
inhibition rate (vi/vo) and the total inhibitor concen-
tration (It) are known. For the simple systems, under
steady-state conditions, these relationships depend
on the Ks constant, on the relevant inhibition con-
stant(s) as well as on the substrate concentration.
The formulae that describe competitive, non-compet-
itive, uncompetitive and mixed type of inhibitions
were taken from Segel [20] and, for convenience,
are given in Table 2. They were derived with the
assumption that catalytic concentrations of enzyme
were present. Therefore, the bound inhibitor could
be neglected and total and free inhibitor concentra-
tions are approximately equal (ItWI). This condi-
tion, however, is often not ful¢lled, especially when
the inhibitor is bound by an enzyme with relatively
high a⁄nity, but not so high as to justify the com-
monly used approach of ‘tightly bound inhibitors’
(see [20,22]). In the latter case, the concentrations
of an inhibitor and an enzyme are comparable, and
therefore, all the possible enzyme^substrate^inhibitor
species must be included in mass balance equations.
The rate relationship that applies to this case was
derived and is given in the Table 2.
For a CM-dependent enzyme system, including the
myosin phosphorylation system considered here, an
inhibitor most often acts to inhibit CM and prevents
its binding to the enzyme. This corresponds to the
classical activator depletion mechanism. Correspond-
ingly, one has to add an additional equilibrium con-
stant to Eq. 1:
Fig. 3. Kinetic characteristics of the substrate-and-activator de-
pletion mechanisms. Concentration of substrate was taken as 60
and that of activator as 0.4 to be approximately the same as
used in most of the experiments with myosin. The diagonal
middle curve illustrates the inhibition by this mechanism as cal-
culated by the derived Eq. 6 with the constants given on the
curve. Note that inhibition by a simple activator depletion
mechanism, with the same constants, was much stronger (activ.
depl., lowest curve). The other two curves correspond to a sim-
ple substrate depletion mechanism of weak (Ksi = 2) and strong
(Ksi = 0.001) inhibition.
Table 2 (continued)
Fractional inhibition rate relationships for most of the inhibition mechanisms applicable to CM-dependent enzyme systems
Type of inhibition Formula: (vi/vo = ) Approximations
Activator depletion multiple site AWKaWKs  AtWKs  AtWS
AtWKaWKs  AWKs  AWS
ItWI
where
A  At
1 I=Kain
Activator-and-substrate depletion see text
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A IIKai AI :
The formula for the fractional inhibition rate for
this case can readily be derived and is given below.
The relative rate, in the absence of inhibitor
vo
vm
 kpWAtWS=KaWKs
1 AtWS=KaWKs  At=Ka
and in the presence of inhibitor
vi
vm
 kpWAWS=KaWKs
1 AWS=KaWKs  A=Ka
After reduction by dividing both sides of these equa-
tions;
vi
vo
 AWKaWKs  AtWKs  AtWS
AtWKaWKs  AWKs  AWS 5
where
A  1=2

It3At Kai234WKai3At
q
3It3At Kai
was obtained in an analogous way as for Eq. 4.
The CM^inhibitor complex can also act as a true
inhibitor and this corresponds to the following equi-
librium:
AI  EIKeaiEAI
and is an example of simple competitive inhibition.
In contrast, derivation of the fractional inhibition
rate relationship for a combination of this mecha-
nism with activator depletion mechanism was only
possible after neglecting the inhibitor bound to the
enzyme, e.g. AtWA+Ai and ItWI+Ai. This relation-
ship is given in Table 2.
These two mechanisms inhibiting the activator are
Fig. 4. Evaluation of inhibition constants for a simple activator depletion (A) and competitive (B) mechanisms of MLCKase inhibition
by CM binding peptide and amiloride, respectively. In A, isolated ReLC (350 WM) was used as the substrate together with CM (300
nM) and the kinase (200 nM). The Kia value obtained after application of non-linear regression analysis together with Eq. 5 was 1.5
nM. In B, the lower curve (closed diamonds) represents inhibition of a reconstituted system with puri¢ed MLCKase (25 nM) and CM
(50 nM) together with isolated regulatory myosin light chain (400 WM) as substrate. The upper curve (open diamonds) corresponds to
a similar inhibition with intact myosin (30 WM) which contained endogenous MLCKase and CM. The middle curve (U) shows that
amiloride acted exclusively at the level of MLCKase because it inhibited phosphorylation of HMM (12.5 WM) which contained an en-
dogenous and Ca2/CM-independent form of the enzyme. The hyperbolic shape of the curves is consistent with a simple competitive
inhibition with Ki of 2.7 WM.
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not the only mechanisms applicable to our system.
Moreover, as is clear from the available data (see
below), the MLCKase system can also be inhibited
at both the activator and the substrate levels. The
corresponding mechanism (activator-and-substrate
depletion) has the following equilibria:
From AI = AtWI/(Kai+I) and SI = StWI/(Ksi+I) a cubic
equation for the free inhibitor was obtained
(I3+aWI2+bWI+c = 0) where the coe⁄cients are:
a = Kai+Ksi+St+At ;
b = KiaWKis+KaWSt+KsiWAt3ItW(Kai+Ksi) ;
c =3KaiWKsiWIt.
From the three real solutions of this equation the
one satisfying initial conditions is given by the fol-
lowing formula:
I  32W

Q
p
WcosTh 2W355=113=33a=3
where
Th  arcosR=

Q
p

while Q and R are de¢ned as in a standard cubic
equation (e.g. Q = (a233b)/9 and R = (2a339aWb+
27c)/54) and 355/113 is Z.
With the known free inhibitor concentration, the
free activator (A) and free substrate (S) are obtained
from the two expressions used above:
A  AtWKai=I  Kai and S  StWKsi=I  Ksi:
Finally, the following formula was obtained for the
relative inhibitory rate:
vi
vo
 AWSWKaWKs  AtWSt  AtWKs
AtWStWKaWKs  AWS  AWKs 6
As illustrated in Fig. 3, the important feature of
this mechanism is that, under common experimental
Fig. 5. Substrate depletion type inhibitions of MLCKase by tri£uoperazine (A) and cadmium chloride (B). (A) TFP inhibition of CM-
independent phosphorylation of heavy meromyosin (HMM). The HMM (42 WM) contained endogenous Ca2/CM-independent kinase
and was phosphorylated in the presence of 2 mM EGTA. The shape of the inhibition curve indicates a simple substrate depletion
type mechanism with Kis of 3 WM. (B) Cadmium inhibition of ReLC phosphorylation by depletion of ATP. CaCl2 (0.1 mM) was
present together with increasing concentrations of CdCl2. ATP (150 WM) was added to initiate phosphorylation. MLCKase and CM
concentrations were 25 and 50 nM, respectively.
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conditions, the additional inhibition at the substrate
level actually removes the inhibition at the lower
range of inhibitor concentration. This is a conse-
quence of the relatively high concentration of the
substrate which acts to deplete the inhibitor before
its levels become su⁄cient to inhibit the activator.
3.4. Evaluation of inhibition constants
Fig. 4 demonstrates the application of non-linear
regression software, together with the fractional in-
hibition rate formula, in evaluation of the inhibition
constants. As an initial example, I used the inhibition
of MLCKase (Fig. 4A) by the CM-binding peptide
which has the same sequence as the CM-domain of
the kinase. Despite the high concentration of the
peptide required for inhibition, the 1.2 nM value of
the derived inhibition constant was in a good agree-
ment with the observed a⁄nity of the kinase for CM.
The second example involved inhibition by a com-
monly used drug, amiloride, and was selected be-
cause of its simple mechanism of inhibition (Fig.
4B). From the hyperbolic shape of the inhibition
curves, it is apparent that this drug acted at the en-
zyme level and not at the level of CM. This was
independently con¢rmed by inhibition of the CM/
Ca-independent phosphorylation of smooth muscle
HMM (Fig. 4B). The ¢tting procedure applied to a
single inhibition curve provided a good estimate of
the amiloride inhibition constant (Ki = 0.8 WM) and
indicates that the competitive inhibition rate formula
can be used.
The procedure can also be used to estimate of
the dissociation constant which characterize the
binding of a substrate to the enzyme (Ks), provided
that the Ki value is known. Relatively accurate data
obtained at several concentrations of substrate can
provide values for both the Ki and Ks constants. In
the latter case, a function of the two independent
variables (It and S) have to be used the way it
was done for a family of CM activation curves
(e.g. Fig. 1).
Fig. 6. Inhibition of myosin (solid diamonds) and the isolated ReLC (open diamonds) phosphorylation by melittin (A) and removal
of this inhibition by addition of thiophosphorylated ReLC (B). The myosin contained endogenous MLCKase and CM (see [8]) and
its concentration was 25 and 40 WM, respectively in A and B. For the ReLC substrate system, 250 WM of ReLC was used and 50 nM
of puri¢ed kinase and 75 nM of CM were added. Note that concentration of melittin at which the inhibition was taking place corre-
lated with neither the substrate nor with the activator concentrations and that the substrate and activator depletion model (Eq. 6) ¢t
the data well.
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3.5. Substrate depletion mechanism
An inhibitor may interact with a substrate and in
this way reduce the reaction rate. This can be a sim-
ple substrate depletion characterized by a bell-shaped
inhibition curve when the inhibitor and the substrate
concentrations are in the same range and the corre-
sponding binding and inhibition constants are ap-
proximately the same. The fractional rate relation-
ship corresponding to this case is given in Table 2.
The mechanism was implied in inhibition of
MLCKase by tri£uoperazine [23] and this was inde-
pendently con¢rmed in my previous report [15]. A
clear-cut example of this type of mechanism is inhi-
bition, by tri£uoperazine (TFP) of the CM-independ-
ent form of MLCKase at its catalytic concentration.
This form of the kinase copur¢es with the soluble
myosin head subfragment (Sobieszek, unpublished
observations). The bell-shaped inhibition curves
(Fig. 5A) and the values of the inhibition constants
(Table 3) were consistent with the suggested sub-
strate depletion mechanism.
Another illustration of a possible substrate deple-
tion mechanism is shown in Fig. 5B. The ¢gure
shows inhibition of the ReLC phosphorylation by
cadmium. Because of its relatively high a⁄nity for
ATP, the cadmium ion replaces Mg from ATP and
the (Cd)ATP complex does not serve as the substrate
in the phosphorylation thus depleting ATP, the sec-
ond substrate of the system. This interpretation was
con¢rmed by the suggested approach. The cadmium^
ATP binding constant (Kis = 7 WM) compares rea-
listically with that obtained from direct binding
experiments [24]. The binding or depletion of
the other substrate (ReLC) was considered very un-
likely because of its low a⁄nity for divalent cati-
ons.
A more complicated rate formula is obtained
when, in addition to substrate depletion, the SI com-
plex acts as an inhibitor of the enzyme. In this case,
there is an additional equilibrium: ES+I [ESI] or its
equivalent E+SI [ESI]. The derived fractional in-
hibition rate formula is given in Table 2. The simpler
case of exclusive SI inhibition was also considered as
Fig. 7. Inhibition of the two MLCKase phosphorylating systems by TFP (A) and CAL (B). The average inhibition constants obtained
from this type of inhibition curves are given in Table 3. The myosin curves are marked by solid diamonds and these ReLC by open
diamonds. The concentrations were 32.5 and 24 WM in (A) and, 100 and 150 WM in (B), for myosin and ReLC, respectively. Note
that for TFP inhibition (A) substrate-and-activator model (Eq. 6) ¢t the data well, but this model was unsatisfactory for inhibition by
CAL (B, broken curve). A multiple site activator depletion mechanism (see Table 2) gave a better ¢t of the data.
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well as other possible mechanisms which may be ap-
plicable for the CM-dependent enzymes systems (see
Table 2).
3.6. Inhibition of the native-like myosin
phosphorylating system
With the Ka and Ks values established, it was pos-
sible to evaluate the Kia and Kis inhibition constants
which characterize the binding of an antagonist by
CM and by the substrate. Such a determination for
melittin (one of the strongest CM-antagonists
known) is shown in Fig. 6A. It is clear that melittin
(MEL) inhibited myosin phosphorylation with much
lower potency than would be expected from its
0.1 nM binding constant for CM [25]. Inhibition re-
quired melittin concentrations of at least 0.5^4 WM,
which is much more than the concentration of en-
dogenous CM estimated previously to be about
100 nM [8] and considerably less than the concentra-
tion of myosin (25^50 WM). Because the inhibition
also depended on the substrate concentration, it was
apparent that the substrate and activator depletion
mechanism was applicable here. Application of the
derived rate relationship formula described the inhi-
bition data rather well not only for the native-like
myosin system, but also with the ReLC as the sub-
strate (Fig. 6A). The values of the inhibition con-
stants obtained for this antagonist are given in Table
3.
An independent con¢rmation of the antagonist
binding by the substrate (here ReLC) was shown in
an experiment in which thiophosphorylated ReLC
was added to the myosin system (Fig. 6B). This addi-
tional free light chain could compete with myosin for
melittin without increasing the concentration of the
available phophorylation sites. As shown in Fig. 6B,
this addition led to the removal of inhibition as a
result of the binding of antagonist to the ReLC.
This light chain (as well as the normally phosphoryl-
ated one) was shown to act as a weak product in-
hibitor (Sobieszek, unpublished observation; see also
[14]); therefore it did not bind to the kinase. Consis-
tent with this interpretation, the inhibition of the
Fig. 8. Comparison of TFP (A) and CAL (B) inhibition of the native-like myosin system with the system reconstituted from the puri-
¢ed components. Note the similar inhibition curves despite the di¡erences in the concentration of myosin, MLCKase and CM. For
more details see text. In A and B, concentrations of the native-like myosin (solid diamonds) were 31 and 33 WM, respectively, while
that of the puri¢ed myosin (crosses) was 23 and 37 WM. The concentrations of MLCKase and CM added to the puri¢ed myosin were
68 and 91 nM, respectively in A and B.
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ReLC system under comparable conditions was
weaker (Fig. 6A).
On the basis of similar competition experiments
with the unphosphorylated ReLC, it was concluded
previously that tri£uoperazine (TFP) inhibited myo-
sin phosphorylation by a similar substrate and acti-
vator depletion mechanism [15]. The present ap-
proach con¢rmed this conclusion (Fig. 7A) and
provided not only the values of the two correspond-
ing inhibition constants, but also the binding stoichi-
ometry (Table 3).
A similar analysis was carried out for the inhibi-
tion by calmidazolium (CAL). In this case, the sub-
strate and activator depletion rate formula did not ¢t
to the CAL inhibition curves well (Fig. 7B). They
were better approximated by a multiple-site activator
depletion mechanism. The corresponding inhibition
constant and binding stoichiometry are given in Ta-
ble 3. The mechanism of CAL inhibition suggested
previously [15] was also of this type although the
multiple-site inhibition could not explicitly be con-
cluded from this study.
The validity of this approach was apparent from
the inhibition data obtained with myosin reconsti-
tuted system in comparison to the native-like myosin
system (Fig. 8). In this case, puri¢ed MLCKase and
CM were added to MLCKase-, and CM-free ¢la-
mentous myosin, and the inhibition data were data
collected in parallel experiments. The concentrations
of the kinase and CM were chosen to ensure linear
32P-incorporation and were not to be the same as in
the native-like myosin. As shown in Fig. 8, the TFP
and CAL inhibition curves were similar for both my-
osins. Signi¢cantly, the inhibition constants obtained
from these parallel experiments were also the same
within the experimental error despite the di¡erences
in the concentration of the substrates, MLCKase and
CM. This con¢rms the validity of the approach and
indicates that the corresponding fractional rate rela-
tionships and the deduced inhibitory mechanisms are
correct.
4. Discussion
Smooth muscle MLCKase is, in addition to CaM
kinase II, one of the most intensively studied CM-
dependent enzymes. The main approach used to elu-
cidate their regulatory mechanisms is genetic engi-
neering (site-directed mutagenesis) together with sim-
ple activity measurements in the presence or absence
of Ca2/CM (for references see [26]). This approach
is, perhaps, justi¢ed with CaM kinase II because its
activity is modulated by CM and depends, in a com-
plex way, on many additional factors (see review
[27]). In the case of MLCKase, however, such a sim-
ple approach is not justi¢ed because its activity de-
pends only on concentrations of CM and Ca2. Ini-
tial attempts to derive corresponding mathematical
model were not particularly encouraging. The gener-
al relationship derived by Huang and King [9] failed,
in our hands (see [18]), to describe related experimen-
tal data, although it included as many as nine bind-
ing constants. A simpler two-constant formula used
by Blumenthal and Stull [28] for skeletal muscle
MLCKase data is satisfactory except that it is only
Table 3
Inhibition constants of myosin phosphorylation evaluated by the approach suggested in the present study
Antagonist Substrate Kia Kis (WM) na
TFP MY 3 þ 2 4 þ 2 2
ReLC 8 þ 4 15 þ 2 1
HMM n.a.b 6 þ 2 2
CAL MY 1.5 þ 0.5W1033 n.a. 4 þ 1
ReLC 0.7 þ 0.3W1034 n.a. 3 þ 1
MEL MY 1.5-4.5W1034 10 þ 0.3 1
ReLC 3W1034 10 þ 0.5 2
aBinding stoichiometry per ReLC or myosin head.
bn.a., not applicable.
BBAMCR 14471 26-4-99
A. Sobieszek / Biochimica et Biophysica Acta 1450 (1999) 77^91 89
valid in the presence of excess of CM. These condi-
tions are, however, less informative than when the
concentrations of the kinase and CM are compara-
ble.
The model derived in the present study describes
MLCKase phosphorylation rate in terms of free
Ca2, total MLCKase and total CM concentrations
and includes only the three related binding constants.
It was applied to phosphorylation rate data obtained
with the two substrates; namely, puri¢ed ¢lamentous
myosin and its isolated ReLC. With the use of a
personal computer and our non-linear regression
software, it is apparent that the model ¢ts the data
rather well. The values of the binding and kinetic
constants obtained characterized well the interaction
between Ca2, CM and MLCKase. They also agreed
well with the corresponding values expected from the
published data (see [5]). In addition, the character-
ization made it possible to con¢rm di¡erences in ac-
tivation of the kinase by a Ca2/CM complex in the
presence of two substrates (intact myosin or its iso-
lated ReLC). From this, it was apparent that intact
myosin is a better substrate for MLCKase than its
isolated ReLC because it increased positive coopera-
tivity during activation of the complex. The mecha-
nism of this increase was not investigated here, but it
could arise from the oligomeric properties of the kin-
ase shown in our recent studies (see [29]) because
only the oligomeric forms of MLCKase appears to
be associated with myosin ¢laments [30].
The present study was undertaken not only to
understand the interaction between MLCKase and
CM better, but also to make it possible to use the
smooth muscle myosin phosphorylating system to
study the action of CM-antagonists. As demon-
strated here, the native-like ¢lamentous myosin prep-
aration which contains stoichiometric amounts of
MLCKase and CM [8] is particularly convenient
for most of the inhibition experiments. During our
computer modeling, it was apparent that, under
common experimental conditions, inhibition of the
phosphorylates rates depended more strongly on
the concentrations of the substrates than on the con-
centration of the CM^MLCKase complex. Thus,
concentrations of the substrates have to be given
rather accurately, but not necessarily those of the
endogenous MLCKase and CM. The approximate
1:150 molar ratio of MLCKase to myosin estab-
lished for the present study can be used as a good
estimate in the computer analysis. If necessary, the
exact CM^MLCKase content can be evaluated as
has been described previously (see [12]). Values of
the other elementary kinetic constants needed for
such an analysis have been estimated and are given
in Table 1. Under the conditions used, the activity of
the system will not depend on other factors such as
Ca2 because this was added in excess and will sat-
urate all the CM present. In view of the exceptionally
high a⁄nity of the Ca2-saturated CM complex for
MLCKase the concentrations of free CM and free
kinase can be neglected.
The steady-state relationships between fractional
inhibitory rate and total inhibitor concentration
have been derived for the above experimental condi-
tions. They cover most of the kinetic inhibitory
mechanisms which are applicable both to the
MLCKase system and to other CM-dependent en-
zymes. Some of these inhibitory models were then
tested on experimental data obtained from this na-
tive-like myosin preparation and by application of a
non-linear regression software. From the analysis of
several inhibitors, it was apparent that the relation-
ships, together with non-linear regression software,
can be used to elucidate at least some inhibitory
mechanisms. This approach can, therefore, be recom-
mended for analysis of inhibitory mechanisms and
for evaluation of related constants of MLCKase
and other CM-dependent enzymes. The general sig-
ni¢cance of non-linear regression analysis in enzyme
kinetics was appropriately emphasized in a recent
book review ([31]; see also [32]).
In contrast to the recommended approach, inhi-
bition of enzyme systems is most often characterized
by measurements of fractional inhibition rate as a
function of total inhibitor concentration (see review
by [33]). The usefulness of the I50 values obtained
from these types of measurements is, however, rather
limited because they do not indicate the kinetic
mechanism of the inhibition. Such values are only
valid for correlating potencies among inhibitors
studied under identical conditions. The approach
suggested here can be used together with any modern
personal computers which are now widely avail-
able.
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